Chymase inhibition prevents fibronectin and myofibrillar loss and improves cardiomyocyte function and LV torsion angle in dogs with isolated mitral regurgitation.

Center for Heart Failure Research, Department of Medicine, University of Alabama at Birmingham, AL 35294-2180, USA.
Circulation (Impact Factor: 14.95). 09/2010; 122(15):1488-95. DOI: 10.1161/CIRCULATIONAHA.109.921619
Source: PubMed

ABSTRACT The left ventricular (LV) dilatation of isolated mitral regurgitation (MR) is associated with an increase in chymase and a decrease in interstitial collagen and extracellular matrix. In addition to profibrotic effects, chymase has significant antifibrotic actions because it activates matrix metalloproteinases and kallikrein and degrades fibronectin. Thus, we hypothesize that chymase inhibitor (CI) will attenuate extracellular matrix loss and LV remodeling in MR.
We studied dogs with 4 months of untreated MR (MR; n=9) or MR treated with CI (MR+CI; n=8). Cine MRI demonstrated a >40% increase in LV end-diastolic volume in both groups, consistent with a failure of CI to improve a 25% decrease in interstitial collagen in MR. However, LV cardiomyocyte fractional shortening was decreased in MR versus normal dogs (3.71±0.24% versus 4.81±0.31%; P<0.05) and normalized in MR+CI dogs (4.85±0.44%). MRI with tissue tagging demonstrated an increase in LV torsion angle in MR+CI versus MR dogs. CI normalized the significant decrease in fibronectin and FAK phosphorylation and prevented cardiomyocyte myofibrillar degeneration in MR dogs. In addition, total titin and its stiffer isoform were increased in the LV epicardium and paralleled the changes in fibronectin and FAK phosphorylation in MR+CI dogs.
These results suggest that chymase disrupts cell surface-fibronectin connections and FAK phosphorylation that can adversely affect cardiomyocyte myofibrillar structure and function. The greater effect of CI on epicardial versus endocardial titin and noncollagen cell surface proteins may be responsible for the increase in torsion angle in chronic MR.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Angiotensin-(1-12) [Ang-(1-12)], a new member of the renin-angiotensin system, is recognized as a renin independent precursor for Ang II. However, the processing of Ang-(1-12) in the circulation in vivo is not fully established. We examined the effect of angiotensin converting enzyme (ACE) and chymase inhibition on angiotensin peptides formation during an intravenous infusion of Ang-(1-12) in normotensive Wistar Kyoto (WKY) and spontaneously hypertensive (SHR) rats. WKY and SHR were assigned to a short Ang-(1-12) infusion lasting 5, 15, 30, or 60 minutes (n=4-10 each group). In another experiment WKY and SHR were assigned to a continuous 15 minute Ang-(1-12) infusion with pretreatment of saline, lisinopril (10 mg/kg), or chymostatin (10 mg/kg) (n=7-13 each group). Saline or lisinopril were infused intravenously 15 minutes prior to the administration of Ang-(1-12) (2 nmol/kg/min) while chymostatin was given by bolus intraperitoneal injection 30 minutes prior to Ang-(1-12). Infusion of Ang-(1-12) increased arterial pressure and plasma Ang-(1-12), Ang I, Ang II, and Ang-(1-7) levels in WKY and SHR. Pretreatment with lisinopril caused increase in Ang-(1-12) and Ang I and large decreases in Ang II compared to the other two groups in both strains. Pretreatment of chymostatin had no effect on Ang-(1-12), Ang I, and Ang II levels in both strains, while it increased Ang-(1-7) levels in WKY. We conclude that ACE acts as the primary enzyme for the conversion of Ang-(1-12) to smaller angiotensin peptides in the circulation of WKY and SHR and that chymase may be an Ang-(1-7) degrading enzyme.
    AJP Heart and Circulatory Physiology 06/2013; · 4.01 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The classical view of biochemical pathways for the formation of biologically active angiotensins continues to undergo significant revision as new data uncovers the existence of important species differences between humans and rodents. The discovery of two novel substrates that, cleaved from angiotensinogen, can lead to direct tissue angiotensin II formation has the potential of radically altering our understanding of how tissues source angiotensin II production and explain the relative lack of efficacy that characterizes the use of angiotensin converting enzyme inhibitors in cardiovascular disease. This review addresses the discovery of angiotensin-(1-12) as an endogenous substrate for the production of biologically active angiotensin peptides by a non-renin dependent mechanism and the revealing role of cardiac chymase as the angiotensin II convertase in the human heart. This new information provides a renewed argument for exploring the role of chymase inhibitors in the correction of cardiac arrhythmias and left ventricular systolic and diastolic dysfunction.
    Current Hypertension Reports 05/2014; 16(5):429. · 3.90 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cardiac ischemia and reperfusion (I/R) injury occurs because the acute increase in oxidative/inflammatory stress during reperfusion culminates in the death of cardiomyocytes. Currently, there is no drug utilized clinically that attenuates I/R injury in patients. Previous studies have demonstrated degranulation of mast cell contents into the interstitium after I/R. Using a dog model of I/R, we tested the role of chymase, a mast cell protease, in cardiomyocyte injury using a specific oral chymase inhibitor (CI). 15 adult mongrel dogs had left anterior descending artery occlusion for 60 min and reperfusion for 100 minutes. 9 dogs received vehicle and 6 were pretreated with a specific CI. In vivo cardiac microdialysis demonstrated a 3-fold increase in interstitial fluid chymase activity in I/R region that was significantly decreased by CI. CI pretreatment significantly attenuated loss of laminin, focal adhesion complex disruption, and release of troponin I into the circulation. Microarray analysis identified an I/R induced 17-fold increase in nuclear receptor subfamily 4A1 (NR4A1) and significantly decreased by CI. NR4A1 normally resides in the nucleus but can induce cell death on migration to the cytoplasm. I/R caused significant increase in NR4A1 protein expression and cytoplasmic translocation, and mitochondrial degradation, which were decreased by CI. Immunohistochemistry also revealed a high concentration of chymase within cardiomyocytes after I/R. In vitro, chymase added to culture HL-1 cardiomyocytes entered the cytoplasm and nucleus in a dynamin-dependent fashion, and promoted cytoplasmic translocation of NR4A1 protein. shRNA knockdown of NR4A1 on pre-treatment of HL-1 cells with CI significantly decreased chymase-induced cell death and mitochondrial damage. These results suggest that the beneficial effects of an orally active CI during I/R are mediated in the cardiac interstitium as well as within the cardiomyocyte due to a heretofore-unrecognized chymase entry into cardiomyocytes.
    PLoS ONE 04/2014; 9(4):e94732. · 3.53 Impact Factor

Full-text (2 Sources)

Available from
Jun 5, 2014